Affiliations: [a] Department of Medicine, Division of Neurology, Jichi Medical University, Tochigi, Japan
| [b] Department of Medicine, Kamitsuga General Hospital, Tochigi, Japan
| [c] Department of Internal Medicine, Imai Hospital, Tochigi, Japan
Correspondence:
[*]
Correspondence to: Kosuke Matsuzono, MD, PhD, Department of Medicine, Division of Neurology, Jichi Medical University, Yakushiji 3311-1, Shimotsuke, Tochigi 329-0498, Japan. Tel.: +81 285 58 7352; Fax: +81 285 44 5118; E-mail: kmatsuzono51@jichi.ac.jp; ORCID: 0000-0002-9455-3903.
Abstract: Background:While many studies focus on the prognosis of individual neurological diseases, very few comprehensively compare and analyze real-world data of these diseases. Objective:To address this gap in knowledge, in this study, we comprehensively analyzed the real-life data of patients with neurological diseases. Methods:We prospectively enrolled patients with neurological diseases at three hospitals from December 1, 2016 to September 30, 2020. Neurological diseases were classified into nine groups: Dementia, Cerebrovascular disease, Parkinson’s and related, Functional, Spinocerebellar degeneration, Neuroimmune, Epilepsy, Muscle dystrophy disease, and Hypertension. Patients were followed up for three years, and their prognosis and evaluation of their cognitive function served as the endpoint. Results:A total of 426 patients were finally enrolled. Both mortality and cognitive function differed among the neurological disease categories. After 3 years, mortality was highest in the Dementia (25.5%), Parkinson’s and related (21.6%), and Spinocerebellar degeneration (35.3%) groups while the cognitive function of patients in these three groups was significantly lowest. Conclusions:When the neurological diseases were holistically observed, both mortality and cognitive function of the Dementia, Parkinson’s and related, and Spinocerebellar degeneration groups were significantly worse than the remaining diseases.
